Browsing by Author "Mbabazi, William"

Now showing 1 - 4 of 4
  • Thumbnail Image
    Item
    Ebola Hemorrhagic Fever Associated with Novel Virus Strain, Uganda, 2007–2008
    (Emerging infectious diseases, 2010) Wamala, Joseph F.; Lukwago, Luswa; Malimbo, Mugagga; Nguku, Patrick; Yoti, Zabulon; Musenero, Monica; Amone, Jackson; Mbabazi, William; Nanyunja, Miriam; Zaramba, Sam; Opio, Alex; Lutwama, Julius J.; Talisuna, Ambrose O.; Okware, Sam I.
    During August 2007–February 2008, the novel Bundibugyo ebola virus species was identified during an outbreak of Ebola viral hemorrhagic fever in Bundibugyo district, western Uganda. To characterize the outbreak as a requisite for determining response, we instituted a caseseries investigation. We identified 192 suspected cases, of which 42 (22%) were laboratory positive for the novel species; 74 (38%) were probable, and 77 (40%) were negative. Laboratory confirmation lagged behind outbreak verification by 3 months. Bundibugyo ebola virus was less fatal (case fatality rate 34%) than Ebola viruses that had caused previous outbreaks in the region, and most transmission was associated with handling of dead persons without appropriate protection (adjusted odds ratio 3.83, 95% confidence interval 1.78–8.23). Our study highlights the need for maintaining a high index of suspicion for viral hemorrhagic fevers among healthcare workers, building local capacity for laboratory confirmation of viral hemorrhagic fevers, and institutionalizing standard precautions.
  • Thumbnail Image
    Item
    Emerging epidemic of iatrogenic Acute Flaccid Paralysis in children under 15 years in Uganda
    (Pan African Medical Journal, 2012) Kisakye, Annet; Ndungutse, David; Byarugaba, Justus; Naddumba, Edward.K.; Mbabazi, William; Bakamutumaho, Barnabas; Bwogi, Josephine; Bakainaga, Andrew; Seruyange, Rachel; Mwesigye, Innocent; Ndugwa, Christopher M.
    Poliomyelitis a differential diagnosis of Acute Flaccid Paralysis (AFP) is a major disability. The prevalence of AFP associated with an intramuscular gluteal injection (s) among children below 15 years of age with fever reported through the AFP surveillance system between 2002 and 2008 in Uganda was studied. Methods A cross sectional study using AFP surveillance data. Any child aged below 15 years, who developed sudden flaccid paralysis between 1st January 2002 and 31st December 2008 was enrolled. NPEC conducted a desk review of completed AFP investigation forms for final classification. A case of an Injection Related Paralysis was defined as sudden onset of flaccid paralysis setting in within 72 hours of receipt of a gluteal intramuscular injection.
  • Thumbnail Image
    Item
    Surveillance for Streptococcus pneumoniae Meningitis in Children Aged !5 Years: Implications for Immunization in Uganda
    (Clinical Infectious Diseases, 2009) Kisakye, Annet; Makumbi, Issa; Nansera, Denis; Lewis, Rosamund; Braka, Fiona; Wobudeya, Eric; Chaplain, Duku; Nalumansi, Esther; Mbabazi, William; Gessner, Bradford D.
    Affordable pneumococcal conjugate vaccines will soon become available to developing countries through the Global Alliance for Vaccines and Immunization. Data on Streptococcus pneumoniae meningitis epidemiology in Uganda will assist decision makers in determining the best national vaccine policy. We reviewed acute bacterial meningitis surveillance data for children aged !5 years from 3 sentinel surveillance sites in 3 Ugandan districts collected from 2001 through 2006. Serotype and antibiotic-resistance testing were performed on pneumococcal isolates collected from 2005 through 2006 from the Kampala district in the tropical central region of Uganda. Minimum pneumococcal meningitis incidence estimates were calculated for a portion of the Kampala district and all of the Gulu district, where case ascertainment was more complete. At the 3 sites, 14,388 probable acute bacterial meningitis cases were observed. The most common cause identified was S. pneumoniae ( ; np331 35% of all confirmed cases), which had an overall case fatality ratio of 19%. Yearly pneumococcal meningitis incidence was 3–20 cases per 100,000 population in Kampala versus 28–42 cases per 100,000 population in Gulu. The most commonly identified serotypes were 6A/6B (40%); 43% of isolates were serotypes that are in the available 7-valent pneumococcal conjugate vaccine and 70% are in the proposed 13- valent pneumococcal vaccine. Twenty-five isolates (83%) had intermediate resistance to penicillin but none were fully resistant. Pneumococcal meningitis is common and severe in Uganda, indicating a role for the pneumococcal conjugate vaccine.
  • Thumbnail Image
    Item
    Surveillance for Streptococcus pneumoniae Meningitis in Children Aged <5 Years: Implications for Immunization in Uganda
    (Clinical Infectious Diseases, 2009) Kisakye, Annet; Makumbi, Issa; Nansera, Denis; Lewis, Rosamund; Braka, Fiona; Wobudeya, Eric; Duku, Chaplain; Nalumansi, Esther; Mbabazi, William; Bradford, D. Gessner
    Affordable pneumococcal conjugate vaccines will soon become available to developing countries through the Global Alliance for Vaccines and Immunization. Data on Streptococcus pneumoniae meningitis epidemiology in Uganda will assist decision makers in determining the best national vaccine policy. We reviewed acute bacterial meningitis surveillance data for children aged !5 years from 3 sentinel surveillance sites in 3 Ugandan districts collected from 2001 through 2006. Serotype and antibiotic-resistance testing were performed on pneumococcal isolates collected from 2005 through 2006 from the Kampala district in the tropical central region of Uganda. Minimum pneumococcal meningitis incidence estimates were calculated for a portion of the Kampala district and all of the Gulu district, where case ascertainment was more complete. At the 3 sites, 14,388 probable acute bacterial meningitis cases were observed. The most common cause identified was S. pneumoniae ( ; 35% of all confirmed cases), which had an overall case fatality ratio of 19%. Yearly n p 331 pneumococcal meningitis incidence was 3–20 cases per 100,000 population in Kampala versus 28–42 cases per 100,000 population in Gulu. The most commonly identified serotypes were 6A/6B (40%); 43% of isolates were serotypes that are in the available 7-valent pneumococcal conjugate vaccine and 70% are in the proposed 13- valent pneumococcal vaccine. Twenty-five isolates (83%) had intermediate resistance to penicillin but none were fully resistant. Pneumococcal meningitis is common and severe in Uganda, indicating a role for the pneumococcal conjugate vaccine.